S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
The 3-Stock Retirement Blueprint (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
The 3-Stock Retirement Blueprint (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
The 3-Stock Retirement Blueprint (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
The 3-Stock Retirement Blueprint (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
The 3-Stock Retirement Blueprint (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
The 3-Stock Retirement Blueprint (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
The 3-Stock Retirement Blueprint (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
The 3-Stock Retirement Blueprint (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
The 3-Stock Retirement Blueprint (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
The 3-Stock Retirement Blueprint (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
The 3-Stock Retirement Blueprint (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
The 3-Stock Retirement Blueprint (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
NASDAQ:PRTA

Prothena - PRTA Stock Forecast, Price & News

$65.00
+4.11 (+6.75%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$59.53
$66.03
50-Day Range
$29.01
$65.00
52-Week Range
$21.06
$66.47
Volume
697,409 shs
Average Volume
510,975 shs
Market Capitalization
$3.14 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$78.40

Prothena MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
20.6% Upside
$78.40 Price Target
Short Interest
Healthy
4.61% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.28mentions of Prothena in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$10.20 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.87) to ($3.74) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

638th out of 1,034 stocks

Pharmaceutical Preparations Industry

307th out of 502 stocks

PRTA stock logo

About Prothena (NASDAQ:PRTA) Stock

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Receive PRTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

PRTA Stock News Headlines

Prothena Third Quarter 2022 Earnings: Misses Expectations
Prothena Corporation PLC
Midday Movers: Biogen, Apple, DocuSign and More
Prothena Becomes Oversold (PRTA)
See More Headlines
Receive PRTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

PRTA Company Calendar

Last Earnings
11/04/2021
Today
12/03/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/16/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRTA
Employees
82
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$78.40
High Stock Price Forecast
$120.00
Low Stock Price Forecast
$55.00
Forecasted Upside/Downside
+20.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$66.97 million
Net Margins
-3,036.03%
Pretax Margin
-3,144.08%

Debt

Sales & Book Value

Annual Sales
$200.58 million
Cash Flow
$1.58 per share
Book Value
$8.36 per share

Miscellaneous

Free Float
33,283,000
Market Cap
$3.14 billion
Optionable
Optionable
Beta
0.50

Key Executives

  • Dr. Gene G. Kinney Ph.D.Dr. Gene G. Kinney Ph.D. (Age 53)
    Pres, CEO & Director
    Comp: $1.02M
  • Mr. Tran B. Nguyen M.B.A.Mr. Tran B. Nguyen M.B.A. (Age 48)
    CFO & Chief Strategy Officer
    Comp: $745.35k
  • Mr. Brandon S. Smith (Age 47)
    Chief Operating Officer
    Comp: $648.34k
  • Ms. Carol D. KarpMs. Carol D. Karp (Age 69)
    Chief Regulatory Officer
    Comp: $679.3k
  • Dr. Hideki Garren M.D. (Age 57)
    Ph.D., Chief Medical Officer
    Comp: $859.64k
  • Ms. Karin L. Walker CPAMs. Karin L. Walker CPA (Age 59)
    CPA, Chief Accounting Officer & Controller
  • Dr. Wagner M. ZagoDr. Wagner M. Zago (Age 49)
    Chief Scientific Officer
  • Ms. Jennifer Zibuda
    Director of Investor Relations & Communication
  • Mr. Michael J. MalecekMr. Michael J. Malecek (Age 56)
    Chief Legal Officer
  • Ms. Yvonne M. Tchrakian
    Company Sec.













PRTA Stock - Frequently Asked Questions

Should I buy or sell Prothena stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PRTA shares.
View PRTA analyst ratings
or view top-rated stocks.

What is Prothena's stock price forecast for 2023?

5 equities research analysts have issued 1 year price objectives for Prothena's shares. Their PRTA share price forecasts range from $55.00 to $120.00. On average, they expect the company's stock price to reach $78.40 in the next year. This suggests a possible upside of 20.6% from the stock's current price.
View analysts price targets for PRTA
or view top-rated stocks among Wall Street analysts.

How have PRTA shares performed in 2022?

Prothena's stock was trading at $49.40 at the start of the year. Since then, PRTA shares have increased by 31.6% and is now trading at $65.00.
View the best growth stocks for 2022 here
.

When is Prothena's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our PRTA earnings forecast
.

How were Prothena's earnings last quarter?

Prothena Co. plc (NASDAQ:PRTA) released its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported $2.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.25 by $0.12. The biotechnology company earned $139.17 million during the quarter, compared to analyst estimates of $140.08 million. Prothena had a negative net margin of 3,036.03% and a negative trailing twelve-month return on equity of 36.46%. During the same period last year, the firm posted ($0.77) EPS.

What other stocks do shareholders of Prothena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).

What is Prothena's stock symbol?

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

Who are Prothena's major shareholders?

Prothena's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.49%), Price T Rowe Associates Inc. MD (6.16%), State Street Corp (3.89%), Palo Alto Investors LP (3.41%), First Light Asset Management LLC (3.18%) and Dimensional Fund Advisors LP (3.07%). Insiders that own company stock include Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Gene G Kinney, Hideki Garren, Karin L Walker, Karin L Walker, Lars Ekman, Michael J Malecek, Michael J Malecek, Richard T Collier, Shane Cooke, Tran Nguyen and Wagner M Zago.
View institutional ownership trends
.

How do I buy shares of Prothena?

Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prothena's stock price today?

One share of PRTA stock can currently be purchased for approximately $65.00.

How much money does Prothena make?

Prothena (NASDAQ:PRTA) has a market capitalization of $3.14 billion and generates $200.58 million in revenue each year. The biotechnology company earns $66.97 million in net income (profit) each year or ($3.34) on an earnings per share basis.

How can I contact Prothena?

Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The official website for the company is www.prothena.com. The biotechnology company can be reached via phone at (531) 236-2500, via email at ellen.rose@prothena.com, or via fax at 353-1902-3510.

This page (NASDAQ:PRTA) was last updated on 12/4/2022 by MarketBeat.com Staff